Myriad Genetics, Inc. (NASDAQ:MYGN) belonging to the Medical sector has surged 0.31% and closed its last trading session at $19.21.
The company is expected to report its next EPS on Nov 01 AMC. Currently, the stock has a 1 Year Price Target of $22.6.
The consensus recommendation, according to Zacks Investment research, is 3.31. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 3.02 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 3.02 and 2.38 respectively.
Myriad Genetics, Inc. on 9/30/2016 reported its EPS as $0.36 with the analysts projecting the EPS of the stock as $0.38. The company beat the analyst EPS Estimate with the difference of $-0.02. This shows a surprise factor of -5.3%.
Many analysts have provided their estimated foresights on Myriad Genetics, Inc. Earnings, with 14 analysts believing the company would generate an Average Estimate of $0.26. Whereas they predicted High and Low Earnings Estimate as $0.28 and $0.24 respectively. While in the same Quarter Previous year, the Actual EPS was $0.41.
Analysts are also projecting an Average Revenue Estimate for Myriad Genetics, Inc. as $171.03 Million in the Current Quarter. This estimate is provided by 11 analysts. The High Revenue estimate is predicted as 176 Million, while the Low Revenue Estimate prediction stands at 168 Million. The company’s last year sales total was 183.5 Million.
For the Current Quarter, the growth estimate for Myriad Genetics, Inc. is -36.6%, while for the Next Quarter the stock growth estimate is -37.8%. In the past 5 years, the stock showed growth of 4.17% per annum. While for the next 5 years, the growth estimate is 5.62%.
The Company got Downgrade by Ladenburg Thalmann on 10-Oct-16 from Neutral to Sell.
Insider Trades for Myriad Genetics, Inc. show that the latest trade was made on 29 Sep 2016 where Lanchbury (Jerry S), the Officer completed a transaction type “Sell” in which 5459 shares were traded at a price of $20.58.
6 Insider Sales transactions were made totaling 180270 shares traded.
10 analysts projected Price Targets for Myriad Genetics, Inc.. The analysts believe that the company stock price could grow as high as $42. The Low Price target projection by analysts is $16 and the Mean Price Target is $22.6.
Myriad Genetics, Inc. (NASDAQ:MYGN) has the market capitalization of $1.32 Billion. The company rocked its 52-Week High of $46.24 on Nov 4, 2015 and touched its 52-Week Low of $18.51 on Oct 11, 2016. The stock has Return on Assets (ROA) of 14.7 percent. Return on Equity (ROE) stands at 16.8% and Return on Investment (ROI) of 16.5 percent.
The stock is currently showing YTD performance of -55.49 Percent. The company has Beta Value of 0.41 and ATR value of 0.79. The Weekly and Monthly Volatility stands at 4.64% and 3.96%.
Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.